Codelivery of BCL2 and MCL1 Inhibitors Enabled by Phenylboronic Acid‐Functionalized Polypeptide Nanovehicles for Synergetic and Potent Therapy of Acute Myeloid Leukemia

Codelivery of BCL2 and MCL1 Inhibitors Enabled by Phenylboronic Acid‐Functionalized Polypeptide Nanovehicles for Synergetic and Potent Therapy of Acute Myeloid Leukemia

Abstract Acute myeloid leukemia (AML) is the most refractory hematologic malignancy characterized by acute onset, rapid progression, and high recurrence rate. Here, codelivery of BCL2 (ABT199) and MCL1 (TW37) inhibitors using phenylboronic acid‐functionalized polypeptide nanovehicles to achieve syne...

Full description

Bibliographic Details
Main Authors: Jiguo Xie, Xiaofei Zhao, Peng Zhang, Yueyue Zhang, Ru Cheng, Zhiyuan Zhong, Chao Deng
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Advanced Science
Subjects:
acute myeloid leukemia
BCL2 inhibitor
BN coordination
boronic ester bond
MCL1 inhibitor
synergetic therapy
Online Access:https://doi.org/10.1002/advs.202204866

Internet

https://doi.org/10.1002/advs.202204866

Similar Items